Overview of Adjuvant Systemic Therapy in Early Stage Breast Cancer

Surgical Clinics of North America

Volumn 87, Issue 2, 2007, Pages 499-509

  Newman, Lisa A ^a   Singletary, S Eva ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; METHOTREXATE; PLACEBO; TAMOXIFEN; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALGORITHM; BREAST CANCER; CANCER RESEARCH; CANCER STAGING; CLINICAL RESEARCH; CLINICAL TRIAL; HORMONAL THERAPY; HORMONE RELEASE; HUMAN; MENOPAUSAL SYNDROME; META ANALYSIS; MICROMETASTASIS; MORTALITY; PATIENT SELECTION; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RADIATION DOSE; RELAPSE; REVIEW; RISK REDUCTION; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT SELECTION;

EID: 34248229844     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2007.01.002     Document Type: Review

References (36)

1. Peto R., Boreham J., Clark M., et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355 9217 (2000) 1822
2. Fisher B. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA Cancer J Clin 49 3 (1999) 159-177
3. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320 8 (1989) 479-484
4. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88 21 (1996) 1529-1542
5. Fisher B., Dignam J., Mamounas E.P., et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14 7 (1996) 1982-1992
6. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 319 26 (1988) 1681-1692
7. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352 9132 (1998) 930-942
8. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351 9114 (1998) 1451-1467
9. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
10. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 1 (2002) CD000487
11. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 348 9036 (1996) 1189-1196
12. Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 3 (2000) CD000485
13. Fisher B., Dignam J., Tan-Chiu E., et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 93 2 (2001) 112-120
14. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19 4 (2001) 980-991
15. Adjuvant! On line: Available at: www.adjuvantonline.com. Accessed June 15, 2006.
16. Olivotto I.A., Bajdik C.D., Ravdin P.M., et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23 12 (2005) 2716-2725
17. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 10 (2005) 1569-1583
18. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20 17 (2002) 3628-3636
19. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 27 (2004) 2817-2826
20. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001;(1):CD000486.
21. Fisher B., Powles T.J., and Pritchard K.J. Tamoxifen for the prevention of breast cancer. Eur J Cancer 36 2 (2000) 142-150
22. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 18 (1998) 1371-1388
23. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 9 (2001) 684-690
24. Baum M., Budzar A.U., Cuzik J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 9324 (2002) 2131-2139
25. Goss P, Ingle J, Martino S, et al. Updated analysis of the NCIC CTG MA.17 randomized placebo-controlled trial of letrozole after five years of tamoxifen in postmenopausal women with early stage breast cancer. Presented at the American Society of Clinical Oncology 2004 Annual Meeting. New Orleans (LA), (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004:847.
26. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
27. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
28. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 21 13 (2003) 2597-2599
29. Fisher B., et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 168 3 (1968) 337-356
30. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 6 (2003) 976-983
31. Mamounas E.P., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23 16 (2005) 3686-3696
32. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 22 (2005) 2302-2313
33. Citron M.L. Dose density in adjuvant chemotherapy for breast cancer. Cancer Invest 22 4 (2004) 555-568
34. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 8 (2003) 1431-1439
35. Piccart-Gebhart M.J., Proctor M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1659-1672
36. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684